News

FDA Asks GSK for More Evidence of Mepolizumab’s Ability to Help Treat Flares in COPD Patients

GlaxoSmithKline’s application for approval of mepolizumab as an add-on therapy to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) requires more clinical data, the U.S. Food and Drug Administration (FDA) said in a complete response letter. GSK sought approval for mepolizumab as an add-on to inhaled corticosteroid-based maintenance treatments used…

Two Phase 2 Trials Demonstrate RPL554 Has Potential to Enhance Bronchodilators’ Efficacy in COPD

The addition of Verona Pharma’s investigational agent RPL554 to standard short- and long-acting bronchodilators offers greater clinical benefits to patients with chronic obstructive pulmonary disease (COPD). Results of two Phase 2 clinical trials (NCT02542254 and NCT03028142) demonstrated that the RPL554 add-on could enhance the bronchodilation action…

Testosterone Replacement Therapy Can Slow Men’s COPD, Study Finds

Testosterone replacement therapy can help slow the progression of chronic obstructive pulmonary disease (COPD) in men, a new study shows. Men with COPD tend to experience shortness of breath, leading physicians to prescribe them long-term steroid-based medications. While these medications help treat pulmonary symptoms, they are also associated with…

Switch to Electronic Cigarettes May Help COPD Patients, Study Reports

Electronic cigarettes help reduce exacerbations and improve exercise capacity in patients with chronic obstructive pulmonary disease (COPD) who saw their condition get worse by smoking conventional cigarettes, a new study reports. The study, “Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up” was…

Bevespi Aerosphere Shows Similar Effectiveness as Anoro Elipta in COPD Study

AstraZeneca’s Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) has been shown to have similar therapeutic activity in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) as GlaxoSmithKline’s approved therapy Anoro Elipta (umeclidinium/vilanterol). Bevespi Aerosphere combines a fixed dose of two bronchodilators — glycopyrrolate, a…